Evidence map›Paper›PMID 29402060›Full record

ArticleJournal of stroke2018

Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset.

Mahesh Kate, Robert Wannamaker, Harsha Kamble, Parnian Riaz, Laura C Gioia, Brian Buck, Thomas Jeerakathil, Penelope Smyth, Ashfaq Shuaib, Derek Emery and 1 more

Erratum issued Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of stroke, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04558125 (Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism), which is not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04558125 phase4terminatednot on this mapstarted 2020, after this paper: background citation

Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2020 to 2021Enrolled2ConditionsPulmonary Embolism, COVIDArmsTNKase, Placebo, Enoxaparin
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke.Current treatment options in cardiovascular medicine · 2023
    Review
  6. Observational
  7. Review
  8. Review
  9. Delayed recanalization in acute ischemic stroke patients: Late is better than never?Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019
    Review
  10. Multimodal CT in Acute Stroke.Current neurology and neuroscience reports · 2019
    Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mahesh KateDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Robert WannamakerDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Harsha KambleDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Parnian RiazDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Laura C GioiaDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Brian BuckDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Thomas JeerakathilDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Penelope SmythDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Ashfaq ShuaibDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Derek EmeryDepartment of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada.
Kenneth ButcherDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThrombolysis >4.5 hours after ischemic stroke onset is unproven. We assessed the feasibility of tenecteplase (TNK) treatment in patients with evidence of an ischemic penumbra 4.5 to 24 hours after onset.

methodsAcute ischemic stroke patients underwent perfusion computed tomography (CT)/magnetic resonance imaging. Patients with cerebral blood volume (CBV) or diffusion weighted imaging Alberta Stroke Program Early CT Scores (ASPECTS) >6 and mismatch score >2 (defined as >2 ASPECTS regions with delay on mean transit time maps and normal CBV) were eligible for treatment with TNK (0.25 mg/kg). Patients with mismatch patterns enrolled in non-endovascular/non-thrombolysis trials and those without mismatch patterns served as comparators.

resultsThe median (interquartile range) baseline National Institutes of Health Stroke Scale (NIHSS) in TNK treated patients (n=16) was 12 (range, 8 to 15). In the untreated mismatch (n=18) and nonmismatch (n=23) groups, the baseline NIHSS was 12 (range, 7 to 12) and 16 (range, 8 to 20;

conclusionsThis prospective, non-randomized study supports the feasibility of TNK therapy in patients with evidence of ischemic penumbra 4 to 24 hours after onset.

Indexed as

StrokeTenecteplase

Identifiers

PMID29402060
PMCPMC5836582
OpenAlexW4242991111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.